GSK books £121m in Australian Rx deal with Aspen
This article was originally published in Scrip
GlaxoSmithKline is to make a post-tax gain of £121 million following its latest divestment, in which it is selling a basket of 25 older brands for the Australian market to Aspen Global. The products, non-promoted and genericised drugs which GlaxoSmithKline terms "classic brands", generated sales of £83 million in 2011 and £31 million in the first half of 2012. Revenues have been declining on the products due to local price reductions and generic competition.
You may also be interested in...
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.